Cytogenetic Abnormalities Can Change During the Course of the Disease Process in Chronic Lymphocytic Leukemia
Authors:
- 1 July 2006
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (19) , 3218-3219
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2006
- Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted TherapyJournal of Clinical Oncology, 2006
- ZAP-70 by Flow Cytometry: Comparison of Methodologies, and with IgVH Mutational and ZAP-70 Methylation Status.Blood, 2005
- Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.Blood, 2005
- ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2004
- Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLLBlood, 2004